1/11
07:40 pm
trvi
Is Trevi Therapeutics (TRVI) Building a Multi-Indication Moat With Its Nalbuphine ER Cough Strategy? [Yahoo! Finance]
Low
Report
Is Trevi Therapeutics (TRVI) Building a Multi-Indication Moat With Its Nalbuphine ER Cough Strategy? [Yahoo! Finance]
1/11
06:37 pm
trvi
Trevi Therapeutics (TRVI) Valuation Check After FDA End Of Phase 2 Update And Renewed Analyst Optimism [Yahoo! Finance]
Low
Report
Trevi Therapeutics (TRVI) Valuation Check After FDA End Of Phase 2 Update And Renewed Analyst Optimism [Yahoo! Finance]
1/9
08:02 am
trvi
Trevi Therapeutics (NASDAQ:TRVI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
Low
Report
Trevi Therapeutics (NASDAQ:TRVI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
1/8
08:23 am
trvi
Trevi Therapeutics (NASDAQ:TRVI) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $19.00 price target on the stock.
Low
Report
Trevi Therapeutics (NASDAQ:TRVI) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $19.00 price target on the stock.
1/8
07:30 am
trvi
Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference
Low
Report
Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference
12/23
01:23 pm
trvi
MarketBeat's Top 5 Rated Small-Cap Stocks [Yahoo! Finance]
Low
Report
MarketBeat's Top 5 Rated Small-Cap Stocks [Yahoo! Finance]
12/21
07:42 am
trvi
Trevi Therapeutics (TRVI) Targets Next Phase of Growth with Leadership Change [Yahoo! Finance]
Medium
Report
Trevi Therapeutics (TRVI) Targets Next Phase of Growth with Leadership Change [Yahoo! Finance]
12/19
10:04 am
trvi
Trevi Therapeutics (NASDAQ:TRVI) was given a new $18.00 price target on by analysts at Stifel Nicolaus.
Medium
Report
Trevi Therapeutics (NASDAQ:TRVI) was given a new $18.00 price target on by analysts at Stifel Nicolaus.
12/4
07:30 am
trvi
Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer
Low
Report
Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer
11/21
05:31 am
trvi
Trevi Therapeutics (NASDAQ:TRVI) was upgraded by analysts at B. Riley to a "strong-buy" rating.
Medium
Report
Trevi Therapeutics (NASDAQ:TRVI) was upgraded by analysts at B. Riley to a "strong-buy" rating.
11/19
06:02 am
trvi
Trevi Therapeutics (NASDAQ:TRVI) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
Medium
Report
Trevi Therapeutics (NASDAQ:TRVI) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
11/17
08:45 am
trvi
Trevi Therapeutics: Big Cough Data, Bigger Execution Risk [Seeking Alpha]
Low
Report
Trevi Therapeutics: Big Cough Data, Bigger Execution Risk [Seeking Alpha]
11/15
07:05 pm
trvi
How Trevi Therapeutics' (TRVI) Phase 3 Progress and Fresh Funding May Influence Investor Expectations [Yahoo! Finance]
Low
Report
How Trevi Therapeutics' (TRVI) Phase 3 Progress and Fresh Funding May Influence Investor Expectations [Yahoo! Finance]
11/15
04:40 am
trvi
Trevi Therapeutics (TRVI): Assessing Valuation After Clinical Program Advances and Cash Runway Extension [Yahoo! Finance]
Low
Report
Trevi Therapeutics (TRVI): Assessing Valuation After Clinical Program Advances and Cash Runway Extension [Yahoo! Finance]
11/14
04:18 pm
trvi
Trevi Therapeutics (NASDAQ:TRVI) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $19.00 price target on the stock.
Low
Report
Trevi Therapeutics (NASDAQ:TRVI) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $19.00 price target on the stock.
11/14
09:14 am
trvi
Trevi Therapeutics (NASDAQ:TRVI) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Low
Report
Trevi Therapeutics (NASDAQ:TRVI) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
11/14
09:05 am
trvi
Trevi Therapeutics (NASDAQ:TRVI) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Low
Report
Trevi Therapeutics (NASDAQ:TRVI) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
11/13
09:53 am
trvi
Trevi Therapeutics (NASDAQ:TRVI) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $13.00 price target on the stock.
Medium
Report
Trevi Therapeutics (NASDAQ:TRVI) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $13.00 price target on the stock.
11/6
04:36 pm
trvi
Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025 [Yahoo! Finance]
Low
Report
Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025 [Yahoo! Finance]
11/6
04:05 pm
trvi
Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025
Neutral
Report
Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025
11/4
07:30 am
trvi
Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference
Low
Report
Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference